 <h1>Alogliptin / metformin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of alogliptin/metformin include:</b> lactic acidosis, nausea, vomiting, and hypoglycemia. <b>Other side effects include:</b> upper respiratory tract infection, abdominal distress, headache, and nasopharyngitis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to alogliptin/metformin: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Lactic AcidosisPostmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL.Risk factors include renal impairment, concomitant use of certain drugs, age greater than or equal to 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information.If lactic acidosis is suspected, discontinue alogliptin / metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, alogliptin / metformin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking alogliptin / metformin:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>dizziness</li>
<li>headache</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>chest pain</li>
<li>chills</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>decreased urine output</li>
<li>depression</li>
<li>difficult, burning, or painful urination</li>
<li>dilated neck veins</li>
<li>extreme fatigue</li>
<li>frequent urge to urinate</li>
<li>increased hunger</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>nightmares</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tightness in chest</li>
<li>troubled breathing</li>
<li>unusual tiredness or weakness</li>
<li>weight gain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>constipation</li>
<li>cough</li>
<li>darkened urine</li>
<li>diarrhea</li>
<li>difficulty with swallowing</li>
<li>fever</li>
<li>hives or itching</li>
<li>indigestion</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Dark-colored urine</li>
<li>general feeling of tiredness or weakness</li>
<li>large, hard skin blisters</li>
<li>light-colored stools</li>
<li>redness of the skin</li>
<li>severe joint pain</li>
<li>stomach pain, continuing</li>
<li>welts</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of alogliptin / metformin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>ear congestion</li>
<li>loss of voice</li>
<li>muscle aches</li>
<li>sneezing</li>
<li>stuffy or runny nose</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alogliptin / metformin: oral tablet</i></p><h3>General</h3><p>The most common adverse reactions reported include upper respiratory tract infection, nasopharyngitis, diarrhea, hypertension, headache, back pain, and urinary tract infection.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Diarrhea, gastroenteritis, abdominal pain, vomiting, gastritis, gastroesophageal reflux disease </p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, gastroesophageal reflux disease </p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis </p>
<p><b>Postmarketing reports</b>: Acute pancreatitis</p>
<p></p>
<p>Metformin:</p>
<p><b>Very common</b> (10% or more): Diarrhea (up to 53.2%), Nausea/vomiting (25.5%), flatulence (12.1%)</p>
<p><b>Common</b> (1% to 10%): Indigestion, abdominal discomfort<sup>[Ref]</sup></p><p>Acute pancreatitis has been associated with DPP-4 inhibitors.  In a pooled analysis of 13 studies, the overall rate of pancreatitis reported with alogliptin 25 mg, 12.5 mg, active control, or placebo was 2, 1, 1, or 0, events per 1000 patient years, respectively.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Alogliptin:</p>
<p><b>Postmarketing reports</b>: Hepatic enzyme elevations, fulminant hepatic failure</p>
<p></p>
<p>Metformin:</p>
<p><b>Very rare</b> (less than 0.01%): Hepatitis, liver function test abnormalities<sup>[Ref]</sup></p><p>Cases of hepatic dysfunction including hepatic failure have been received in the postmarketing period with alogliptin-treated patients; causality has not been established.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>In metformin-treated patients, lactic acidosis has been reported in approximately 0.03 cases per 1000 patient-years with approximately half these cases resulting in fatalities.  In more than 20,000 patient-years exposure in clinical trials, there were no cases of lactic acidosis.  Reported cases have occurred primarily in patients with significant renal insufficiency, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications.  </p>
<p></p>
<p>In an alogliptin monotherapy study, the incidence of hypoglycemia was 1.5% (compared with 1.6% in placebo).  Adding alogliptin to glyburide or insulin did not increase the incidence of hypoglycemia compared with placebo.  In elderly patients, the incidence of hypoglycemia was 5.4% with alogliptin compared with 26% for glipizide.  In a 26-week, placebo-controlled study of alogliptin once daily as add-on to a metformin regimen, hypoglycemic events were reported in 0.9% of patients in the alogliptin-metformin group compared with 2.9% in the placebo group.<sup>[Ref]</sup></p><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Hypoglycemia</p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Hypoglycemia </p>
<p></p>
<p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Hypoglycemia, loss of appetite</p>
<p><b>Very rare</b> (less than 0.01%): Lactic acidosis, vitamin B12 deficiency<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Alogliptin:</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (0.6%)</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, rash, urticaria, severe cutaneous adverse reactions (Stevens-Johnson syndrome), erythema multiforme<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><p>Alogliptin-metformin:</p>
<p><b>Common</b> (1% to 10%): Pruritus, rash</p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Pruritus, rash</p>
<p><b>Postmarketing reports</b>: Exfoliative skin conditions including Stevens-Johnson syndrome, angioedema, urticaria</p>
<p></p>
<p>Metformin:</p>
<p><b>Very rare</b> (less than 0.01%): Erythema, pruritus, urticaria</p>
<p></p>
<p>Dipeptidyl peptidase-4 inhibitors:</p>
<p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Upper respiratory tract infection, nasopharyngitis </p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Nasopharyngitis, upper respiratory tract infection </p>
<p></p>
<p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Upper respiratory tract infection, nasopharyngitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Headache </p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Headache </p>
<p></p>
<p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Headache, metallic taste<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>In a clinical trial in patients with recent acute coronary syndrome, a greater proportion of patients receiving this drug were hospitalized for congestive heart failure compared with placebo (3.9% [n=106] vs 3.3% [n=89]),<sup>[Ref]</sup></p><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Hypertension </p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Hypertension </p>
<p><b>Frequency not reported</b>: Heart failure</p>
<p></p>
<p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Urinary tract infection </p>
<p></p>
<p>Alogliptin:</p>
<p><b>Common</b> (1% to 10%): Urinary tract infection </p>
<p></p>
<p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Alogliptin-Metformin:</p>
<p><b>Common</b> (1% to 10%): Back pain </p>
<p></p>
<p>Alogliptin:</p>
<p><b>Uncommon</b> (0.1% to 1%): Back pain</p>
<p><b>Frequency not reported</b>: Arthralgia </p>
<p></p>
<p>Metformin:</p>
<p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Other</h3><p>Metformin: </p>
<p><b>Common</b> (1% to 10%): Asthenia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Kazano (alogliptin-metFORMIN)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm?source=govdelivery&amp;utm_medium=em"   ([11 Feb 2014]):</p><p id="ref_5">5. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p></div>
<div class="more-resources" id="moreResources">
<h2>More about alogliptin / metformin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antidiabetic combinations</li>
<li>FDA Alerts (4)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alogliptin and metformin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Kazano</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alogliptin / metformin: oral tablet</i></p><h3>General</h3><p>The most common adverse reactions reported include upper respiratory tract infection, nasopharyngitis, diarrhea, hypertension, headache, back pain, and urinary tract infection.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Diarrhea, gastroenteritis, abdominal pain, vomiting, gastritis, gastroesophageal reflux disease </p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, gastroesophageal reflux disease </p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis </p><p><b>Postmarketing reports</b>: Acute pancreatitis</p><p></p><p>Metformin:</p><p><b>Very common</b> (10% or more): Diarrhea (up to 53.2%), Nausea/vomiting (25.5%), flatulence (12.1%)</p><p><b>Common</b> (1% to 10%): Indigestion, abdominal discomfort<sup>[Ref]</sup></p><p>Acute pancreatitis has been associated with DPP-4 inhibitors.  In a pooled analysis of 13 studies, the overall rate of pancreatitis reported with alogliptin 25 mg, 12.5 mg, active control, or placebo was 2, 1, 1, or 0, events per 1000 patient years, respectively.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Alogliptin:</p><p><b>Postmarketing reports</b>: Hepatic enzyme elevations, fulminant hepatic failure</p><p></p><p>Metformin:</p><p><b>Very rare</b> (less than 0.01%): Hepatitis, liver function test abnormalities<sup>[Ref]</sup></p><p>Cases of hepatic dysfunction including hepatic failure have been received in the postmarketing period with alogliptin-treated patients; causality has not been established.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>In metformin-treated patients, lactic acidosis has been reported in approximately 0.03 cases per 1000 patient-years with approximately half these cases resulting in fatalities.  In more than 20,000 patient-years exposure in clinical trials, there were no cases of lactic acidosis.  Reported cases have occurred primarily in patients with significant renal insufficiency, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications.  </p><p></p><p>In an alogliptin monotherapy study, the incidence of hypoglycemia was 1.5% (compared with 1.6% in placebo).  Adding alogliptin to glyburide or insulin did not increase the incidence of hypoglycemia compared with placebo.  In elderly patients, the incidence of hypoglycemia was 5.4% with alogliptin compared with 26% for glipizide.  In a 26-week, placebo-controlled study of alogliptin once daily as add-on to a metformin regimen, hypoglycemic events were reported in 0.9% of patients in the alogliptin-metformin group compared with 2.9% in the placebo group.<sup>[Ref]</sup></p><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Hypoglycemia</p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Hypoglycemia </p><p></p><p>Metformin:</p><p><b>Common</b> (1% to 10%): Hypoglycemia, loss of appetite</p><p><b>Very rare</b> (less than 0.01%): Lactic acidosis, vitamin B12 deficiency<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Alogliptin:</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (0.6%)</p><p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, rash, urticaria, severe cutaneous adverse reactions (Stevens-Johnson syndrome), erythema multiforme<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.<sup>[Ref]</sup></p><p>Alogliptin-metformin:</p><p><b>Common</b> (1% to 10%): Pruritus, rash</p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Pruritus, rash</p><p><b>Postmarketing reports</b>: Exfoliative skin conditions including Stevens-Johnson syndrome, angioedema, urticaria</p><p></p><p>Metformin:</p><p><b>Very rare</b> (less than 0.01%): Erythema, pruritus, urticaria</p><p></p><p>Dipeptidyl peptidase-4 inhibitors:</p><p><b>Postmarketing reports</b>: Bullous pemphigoid<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, nasopharyngitis </p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Nasopharyngitis, upper respiratory tract infection </p><p></p><p>Metformin:</p><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, nasopharyngitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Headache </p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Headache </p><p></p><p>Metformin:</p><p><b>Common</b> (1% to 10%): Headache, metallic taste<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>In a clinical trial in patients with recent acute coronary syndrome, a greater proportion of patients receiving this drug were hospitalized for congestive heart failure compared with placebo (3.9% [n=106] vs 3.3% [n=89]),<sup>[Ref]</sup></p><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Hypertension </p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Hypertension </p><p><b>Frequency not reported</b>: Heart failure</p><p></p><p>Metformin:</p><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Urinary tract infection </p><p></p><p>Alogliptin:</p><p><b>Common</b> (1% to 10%): Urinary tract infection </p><p></p><p>Metformin:</p><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Alogliptin-Metformin:</p><p><b>Common</b> (1% to 10%): Back pain </p><p></p><p>Alogliptin:</p><p><b>Uncommon</b> (0.1% to 1%): Back pain</p><p><b>Frequency not reported</b>: Arthralgia </p><p></p><p>Metformin:</p><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Other</h3><p>Metformin: </p><p><b>Common</b> (1% to 10%): Asthenia<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Kazano (alogliptin-metFORMIN)." Takeda Pharmaceuticals America, Lincolnshire, IL. </p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm?source=govdelivery&amp;utm_medium=em"   ([11 Feb 2014]):</p><p id="ref_5">5. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p><h2>More about alogliptin / metformin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antidiabetic combinations</li>
<li>FDA Alerts (4)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alogliptin and metformin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>